Vaccine production facilities
The BioReliance® Services business of Merck KGaA is primarily a Contract Testing Organisation, providing biosafety testing services for a wide range of global, biopharmaceutical companies.
The Glasgow facility also has a biomanufacturing facility. No products are manufactured for direct sale - only contract manufacturing for others. Typical products produced are (i) Cell Banks, (ii) Virus Seed Stocks and (iii) Viral Vectors.
Influenza: Manufacture of influenza vaccine based on WHO recommendations
During 2021 Influenza vaccines and the adjuvant MF59 were manufactured at this facility: four distinct products for the market, Agrippal®, Fluad®, Fluad QIV®, (seasonal influenza strain presentations, the latter two formulated with MF59 adjuvant) and Aflunov (pre-pandemic strain presentation).
Japanese Encephalitis Viral Vaccine
Valneva manufactures Japanese Encephalitis Viral vaccine (IXIARO®/JESPECT®) at its cGMP facilities in Livingston, Scotland. The site is licensed and operates under a Manufacturing Authorisation granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Cobra Biologics, Keele is an MHRA licensed facility for the contract development and manufacture of Investigational Medicinal products; these being cell banks (microbial and mammalian), plasmid DNA and viral vector products for gene therapy uses. Currently the site has a restricted commercial licence granted by the MHRA for the manufacture of COVID-19 vaccine AZD1222 bulk drug substance.
Coronavirus disease (COVID-19)
[Licensed for bulk drug substance manufacturing and testing via MHRA manufacturer’s authorisations MIA 18480 and MIA (IMP) 18480].